CD86 Has Sustained Costimulatory Effects on CD8 T Cells1

CD80 and CD86 both costimulate T cell activation. Their individual effects in vivo are difficult to study as they are coordinately up-regulated on APCs. We have studied mice expressing rat insulin promoter (RIP)-CD80 and RIP-CD86 on the NOD and NOD.scid genetic background to generate in vivo models, using diabetes as a readout for cytotoxic T cell activation. Accelerated spontaneous diabetes onset was observed in NOD-RIP-CD80 mice and the transfer of diabetes from 6-wk-old NOD mice to NOD.scid-RIP-CD80 mice was greater compared with NOD-RIP-CD86 and NOD.scid-RIP-CD86 mice, respectively. However, the secondary in vivo response was maintained if T cells were activated through CD86 costimulation compared with CD80. This was demonstrated by greater ability to cause recurrent diabetes in NOD-RIP-CD86 diabetic mice transplanted with 6-wk-old NOD islets and adoptively transferred diabetes from diabetic NOD-RIP-CD86 mice to NOD.scid mice. In vitro, CD80 costimulation enhanced cytotoxicity, proliferation, and cytokine secretion in activated CD8 T cells compared with CD86 costimulation. We demonstrated increased CTLA-4 and programmed death-1 inhibitory molecule expression following costimulation by both CD80 and CD86 (CD80 > CD86). Furthermore, T cells stimulated by CD80 were more susceptible to inhibition by CD4+CD25+ T cells. Overall, while CD86 does not stimulate an initial response as strongly as CD80, there is greater sustained activity that is seen even in the absence of continued costimulation. These functions have implications for the engineered use of costimulatory molecules in altering immune responses in a therapeutic setting.

[1]  G. Freeman,et al.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.

[2]  D. Sansom,et al.  Integration of CD28 and CTLA‐4 function results in differential responses of T cells to CD80 and CD86 , 2006, European journal of immunology.

[3]  F. Marincola,et al.  Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. , 2005, The Journal of clinical investigation.

[4]  L. Wen,et al.  The influence of the major histocompatibility complex on development of autoimmune diabetes in RIP-B7.1 mice. , 2005, Diabetes.

[5]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[6]  T. Watts,et al.  TNF/TNFR family members in costimulation of T cell responses. , 2005, Annual review of immunology.

[7]  L. Orci,et al.  A CD8+ T-lymphocyte-mediated and CD4+ T-lymphocyte-independent autoimmune diabetes of early onset in transgenic mice , 1994, Diabetologia.

[8]  S. Khoury,et al.  The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice , 2003, The Journal of experimental medicine.

[9]  Andrea Iaboni,et al.  The interaction properties of costimulatory molecules revisited. , 2002, Immunity.

[10]  K. Takeda,et al.  Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells. , 2002, International immunology.

[11]  C. Thompson,et al.  T-cell regulation by CD28 and CTLA-4 , 2001, Nature Reviews Immunology.

[12]  J. Gutiérrez-Ramos,et al.  The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE , 2001, Nature Immunology.

[13]  H. Ochs,et al.  Induction, binding specificity and function of human ICOS , 2000, European journal of immunology.

[14]  G. Freeman,et al.  Mouse Inducible Costimulatory Molecule (ICOS) Expression Is Enhanced by CD28 Costimulation and Regulates Differentiation of CD4+ T Cells1 , 2000, The Journal of Immunology.

[15]  S. Lehar,et al.  The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. , 2000, Immunity.

[16]  C. Janeway,et al.  Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library , 1999, Nature Medicine.

[17]  T. Honjo,et al.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.

[18]  K. Lee,et al.  B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. , 1998, Journal of immunology.

[19]  R. Flavell,et al.  Autoimmunity without diabetes in transgenic mice expressing beta cell-specific CD86, but not CD80: parameters that trigger progression to diabetes. , 1998, Journal of immunology.

[20]  C. Janeway,et al.  The Role of Lymphocyte Subsets in Accelerated Diabetes in Nonobese Diabetic–Rat Insulin Promoter–B7-1 (NOD-RIP-B7-1) Mice , 1998, The Journal of experimental medicine.

[21]  L. A. Stephens,et al.  The threshold for autoimmune T cell killing is influenced by B7‐1 , 1998, European journal of immunology.

[22]  B. Kwon,et al.  Signals through 4-1BB are costimulatory to previously activated splenic T cells and inhibit activation-induced cell death. , 1997, Journal of immunology.

[23]  C. Uyttenhove,et al.  Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. , 1996, Journal of immunology.

[24]  C. Janeway,et al.  CD8 T cell clones from young nonobese diabetic (NOD) islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4 cells , 1996, The Journal of experimental medicine.

[25]  L. A. Stephens,et al.  Pancreatic expression of B7 co-stimulatory molecules in the non-obese diabetic mouse. , 1995, International immunology.

[26]  R. Flavell,et al.  Coexpression of B7-1 and viral ("self") transgenes in pancreatic beta cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes. , 1995, Immunity.

[27]  C. Janeway,et al.  Expression of the Co-stimulator Molecule B7–1 in Pancreatic β-Cells Accelerates Diabetes in the NOD Mouse , 1995, Diabetes.

[28]  V. Kouskoff,et al.  Cassette vectors directing expression of T cell receptor genes in transgenic mice. , 1995, Journal of immunological methods.

[29]  P. Linsley,et al.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. , 1994, Immunity.

[30]  Y. Matsuzawa,et al.  The NOD mouse. , 1994, Diabetes research and clinical practice.

[31]  P. Linsley,et al.  CTLA-4 can function as a negative regulator of T cell activation. , 1994, Immunity.

[32]  P. Linsley,et al.  Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function , 1994, The Journal of experimental medicine.

[33]  P. Linsley,et al.  Costimulator B7-1 confers antigen-presenting-cell function to parenchymal tissue and in conjunction with tumor necrosis factor alpha leads to autoimmunity in transgenic mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Flavell,et al.  The role of the T cell costimulator B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigen. , 1994, Immunity.

[35]  D. Harlan,et al.  Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Bluestone,et al.  Expression and functional significance of an additional ligand for CTLA-4. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  L. Lanier,et al.  B70 antigen is a second ligand for CTLA-4 and CD28 , 1993, Nature.

[38]  P. Linsley,et al.  Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes , 1992, The Journal of experimental medicine.

[39]  J. Gribben,et al.  Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7 , 1991, The Journal of experimental medicine.

[40]  A. Monaco,et al.  IMMUNOLOGICAL CHARACTERISTICS OF PURIFIED PANCREATIC ISLET GRAFTS , 1986, Transplantation.